If AI Healthcare really takes off, these 3 stocks could be amazing.

Artificial intelligence in healthcare is at the intersection of two powerful forces: rapid advances in data-driven medicine and a global focus on making healthcare more efficient and affordable. While bond yields, inflation expectations, and energy prices continue to shift the macro environment, AI healthcare stocks are more tied to long-term trends like early diagnosis, personalized treatments, and faster drug discovery than to short-term swings in sentiment. This article highlights three stocks in the Transformative AI Healthcare screener that apply these tools to real-world problems and provide a focused starting point for further investigation of this subject.

ImExHS (ASX:IME)

overview: ImExHS is a Sydney-based company that provides cloud-based medical imaging software and outsourced radiology services to help hospitals and clinics manage their radiology, cardiology and pathology workflows through the AQUILA, ALULA and ANTEROS platforms.

operation: ImExHS generates approximately A$10 million from software and A$19.2 million from radiology, with total revenues of approximately A$29 million primarily from Latin America.

Market capitalization: AUD 19.5 million

ImExHS sits at the intersection of AI-enabled imaging software and radiology services. Analysts expect profits to turn from a loss of A$2.9 million to a profit of A$5.2 million by 2029, with sales and profits expected to increase in the coming years. The company’s stock trades at a low P/S multiple compared to its healthcare peers, but this could be attractive if you think its cloud-native Aquila+ platform and recurring ARR growth will ultimately support margin growth. At the same time, the business remains in the red, auditors have highlighted going concern uncertainty, and most of its revenue comes from Latin American health systems where payment delays and policy changes could pose major headwinds.

A low P/S and planned swing from loss to profit may make ImExHS look like an overlooked upside, but the whole story lies in analyst forecasts for ImExHS and what that means for its going concern risk.

Singular Health Group (ASX:SHG)

overview: Singular Health Group develops 3DiCom medical imaging software that converts standard 2D scans into interactive 3D models. This allows clinicians and patients to better visualize anatomy for diagnosis and treatment planning, while also providing secure file transfer tools and cloud-based AI to layer automated insights.

operation: Singular Health generates approximately A$1 million from the provision and development of medical technology, of which approximately A$500,000 is attributable to the United States.

Market capitalization: AUD 63.3 million

For a small medical software company still reporting losses, Singular Health is in an interesting position with 3D visualization and AI on the cloud aimed squarely at how clinicians and patients want to interact with image data. Revenue remains below A$1 million and the company has less than a year to raise capital, so its reliance on riskier debt and past shareholder dilution are key red flags. At the same time, the half-year update shows improved revenue and loss per share of A$500,000, while the board is experienced and the stock trades at a lower P/B than some of its peers. Early traction, funding risks, and tensions with management begin to tell the real story.

The early traction of 3D imaging and AI on the cloud may be masking real tensions between funding channels and shareholder dilution, so it’s worth scrutinizing 4 warning signs (3 is significant!) before the next funding chapter unfolds.

Altria (ASX:AYA)

overview: Artrya is a West Perth-based medical technology company developing Salix, a cloud-based AI platform that analyzes coronary CT angiography scans to detect coronary artery disease and helps clinicians identify patients at risk of heart attack.

operation: Artrya currently generates approximately A$0.03 million from the development of its AI-driven CCTA image analysis technology, all of which comes from Australia.

Market capitalization: AUD 757.4 million

Artrya offers AI in cardiac imaging at a very early commercial stage, with revenues still around A$29,000, but with a large potential scan pool through its SAPPHIRE partners, increasing the use of CCTA in chest pain assessment. Analysts are pricing in strong revenue and profit growth forecasts, while the company has around A$76.5 million in cash and is debt-free, giving it time to obtain FDA clearance for its Salix Flow module and expand sales in the US. On the flip side, losses widened to A$10.74 million in the second half, with very low recurring income and significant shareholder dilution. A key consideration for investors is whether future scan volumes and pricing can justify today’s valuation and the growth projections contained in the consensus model.

With Artrya’s cash-rich balance sheet and meager recurring revenue, big questions remain about how quickly adoption will scale, so it’s worth reading analyst forecasts for Artrya before the actual inflection point occurs.

The three stocks mentioned here are just a starting sample. Our complete Transformative Artificial Intelligence (AI) Healthcare Stock Screen reveals six more companies that combine AI-driven diagnostics, personalized care, and increased efficiency with equally compelling stories. Unlock that broad set and use Simply Wall St to identify, filter, and analyze the specific catalysts, risk flags, and business models that best fit your highest-conviction ideas in AI healthcare.

Take control of your investment journey

If Artrya or one of these companies has caught your attention, register for free on Simply Wall St and add your company to your watchlist to monitor stock price relative to fair value and track any new developments. Once migrated, manage your holdings with a portfolio command center that filters out the noise and delivers only the most important and actionable updates. Our community allows you to filter the best ideas from thousands of investor perspectives throughout your journey. Discover hidden catalysts and risks early to accelerate decision-making and stay ahead of the market.

Looking for new alternatives beyond healthcare?

Some of the most interesting ideas quickly go from quiet potential to full-blown breakout before people even realize it. Scan these new sets and act now while it still matters.

• Find resilient compound stocks before their momentum stories get crowded by reviewing six carefully selected resilient stocks with low risk scores that focus on balance sheet strength and measured and disciplined growth paths.
• Seize strong yield opportunities while they’re still flying under the radar by checking out seven hand-picked dividend fortresses designed to combine income and stability.
• Track the companies that power the physical backbone of AI before their valuations start to soar with 46 AI infrastructure stocks focused on chips, data centers, and critical hardware.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.